Severe cerebrovascular and parenchymal lesions in brains of SHRSP were also reduced in both spironolactone- and eplerenone-treated animals[21,22], suggesting that MR inhibition protects against stroke incidence through actions on both vascular and parenchymal tissues. The gene discussed is NR3C2; the disease is stroke disorder.